Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Simultaneously inferring T cell fate and clonality from single cell transcriptomes

ABSTRACT: Simultaneously inferring T cell fate and clonality from single cell transcriptomes

PROVIDER: PRJEB11896 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1146420_1.fastq.gz	Fastqsanger.gz
	ERR1146420_2.fastq.gz	Fastqsanger.gz
	ERR1146430_1.fastq.gz	Fastqsanger.gz
	ERR1146430_2.fastq.gz	Fastqsanger.gz
	ERR1146440_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 544

Similar Datasets

Simultaneously inferring T cell fate and clonality from single cell transcriptomes

Project description:Single-cell RNA-seq from CD4+ T lymphocytes from uninfected steady-state mouse, two mice with Salmonella typhimurium infection at day 14 and one mouse at day 49 post-infection. Used to demonstrate application of reconstruction and analysis of T cell receptor sequences from single-cell RNA-seq.

2016-03-06 | E-MTAB-3857 | biostudies-arrayexpress

Simultaneously discovering the fate and biochemical effects of pharmaceuticals through untargeted metabolomics

Project description:Untargeted metabolomics is an established approach in toxicology for characterising endogenous metabolic responses to xenobiotic exposure. Detecting the xenobiotic and its biotransformation products as part of the metabolomics analysis provides an opportunity to simultaneously gain deep insights into its fate and metabolism, and to associate the xenobiotic’s internal relative dose directly with endogenous metabolic responses. This integration of untargeted exposure and response measurements into a single assay has yet to be fully demonstrated. Here we assembled a workflow to discover and analyse xenobiotic-related measurements from routine untargeted UHPLC-MS metabolomics datasets, derived from in vivo (rat plasma and cardiac tissue, and human plasma) and in vitro (human cardiomyocytes) studies that were principally designed to investigate endogenous metabolic responses to drug exposure. Our findings clearly demonstrate how untargeted metabolomics can discover extensive xenobiotic biotransformation maps, temporally-changing relative systemic exposure, and direct associations of endogenous biochemical responses to the internal dose.

2023-07-03 | MTBLS2746 | MetaboLights

T cell fate and clonality inference from single-cell transcriptomes.

Project description:We developed TraCeR, a computational method to reconstruct full-length, paired T cell receptor (TCR) sequences from T lymphocyte single-cell RNA sequence data. TraCeR links T cell specificity with functional response by revealing clonal relationships between cells alongside their transcriptional profiles. We found that T cell clonotypes in a mouse Salmonella infection model span early activated CD4(+) T cells as well as mature effector and memory cells.

| S-EPMC4835021 | biostudies-literature

A radical switch in clonality reveals the formation of a stem cell niche in the epiphyseal growth plate

Project description:A radical switch in clonality reveals the formation of a stem cell niche in the epiphyseal growth plate

2019-01-03 | GSE113982 | GEO

Cell Fate Control by Engineered Chromatin Regulator

Project description:MS analysis to provide insights into proteins bound to engineered cell fate regulator NanogBiD during somatic cell reprogramming

2023-10-09 | PXD046008 |

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Project description:This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: * Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. * Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. * Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.

| 2257146 | ecrin-mdr-crc

Tox4 Modulates Cell Fate Reprogramming

Project description:Tox4 Modulates Cell Fate Reprogramming

| PRJNA525831 | ENA

Tox4 Modulates Cell Fate Reprogramming

Project description:Tox4 Modulates Cell Fate Reprogramming

| PRJNA525830 | ENA

Inferring Epigenetic and Genetic Biomarkers of cancer in cell-free DNA

Project description:Inferring Epigenetic and Genetic Biomarkers of cancer in cell-free DNA

| PRJNA562656 | ENA

Inferring population dynamics from single-cell RNA-sequencing time-series data

Project description:Inferring population dynamics from single-cell RNA-sequencing time-series data